At the recent ESMO congress, new data was presented showing that upfront treatment with Abiraterone helps patients liver longer.
Hormone injections plus Chemotherapy is standard of care for new diagnosed advanced prostate cancer ( doublet treatment).
A French trial ( PEACE 1) explored the use of Abiraterone in this setting. The investigators found that a “triplet treatment” of Abiraterone + Chemotherapy + Hormone injections would make people live substantially.
This is likely to become standard of care in near future.
Another U.K. trial ( STAMPEDE) assessed Abiraterone in the High risk but less advanced prostate cancer. The study found that adding Abiraterone to the other treatments can improve survival of prostate patients.
This again is likely to become standard of care.
Possible changes in the standard of care for metastatic and non-metastatic prostate cancer. 19 Sep 2021. ESMO Congress 2021
Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.